Active ingredient description

Alefacept interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA15

Chemical formula: C₂₃₀₆H₃₅₉₄N₆₁₀O₆₉₄S₂₆

External identifiers

CAS Substance: 222535-22-0
DrugBank Drug: DB00092
RxNorm Ingredient: 299635
SNOMED-CT Concept: 398691006
Alefacept (substance)
UNII Identifier: ELK3V90G6C